SUBSCRIBE
SUBSCRIBE

LEXEO Therapeutics

NEWS
Photo courtesy of Shutterstock
Drug Development
LEXEO Gene Therapy for Alzheimer’s Shows Early Promise
LEXEO Therapeutics has announced positive initial data from its Phase I/II trial of LX1001, a gene therapy intended for the treatment of APOE4 homozygous Alzheimer’s disease (AD).
March 2, 2022
 · 
3 min read
 · 
Hayley Shasteen
Business
Top Life Sciences Startups to Watch in 2022
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
January 4, 2022
 · 
19 min read
 · 
Heather McKenzie
Biotech Bay
Investors Pour $360 Million into Cutting-Edge Biotechs
Obsidian Therapeutics and three other pharmaceutical companies announced successful Series B raises to propel pipeline candidates further down the track toward clinical studies and approvals.
September 9, 2021
 · 
3 min read
 · 
Kate Goodwin
Load More
AWARDS
  • NextGen Class of 2022
JOBS
IN THE PRESS
Press Releases
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
September 5, 2024
 · 
1 min read
Press Releases
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
August 12, 2024
 · 
7 min read
Press Releases
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
July 15, 2024
 · 
8 min read
Press Releases
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
July 11, 2024
 · 
4 min read
News
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
July 8, 2024
 · 
2 min read
Business
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
May 9, 2024
 · 
7 min read
Pharm Country
Lexeo Therapeutics to Participate in Upcoming May 2024 Investor Conferences
May 7, 2024
 · 
1 min read
Business
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
April 22, 2024
 · 
7 min read
FDA
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
April 16, 2024
 · 
5 min read
Pharm Country
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
March 13, 2024
 · 
5 min read
Load More